Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

ADMA Biologics, Inc. ADMA

Set alert

Price alert · ADMA

All alert types
11.06 USD -0.35 -3.07%

At close

11.29 +0.23 +2.08%

Pre-market · Nov 3, 4:13 AM ET

Bid
11.05 × 1
Ask
11.06 × 1
11.05 Day range 11.59
7.21 52-week range 20.46
YTD
-39.36%
1 year
-28.04%
Open
11.42
Prev close
11.41
Mkt cap
2.48B
Vol
2.89M
Avg vol
2.69M
EPS
0.70
P/E
15.80
Div yield
0.00%
More statistics
Low
11.05
High
11.59
Forward P/E
11.72
Beta
0.66
Short ratio
5.82
Inst. own
92.54%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
10.00
200-d avg
10.96
1y target
17.00

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 5, 2026Earnings: 0.16; estimate 0.1633; surprise -2.02%
Signals (14)
NameDateAgo
RSI: OverboughtOct 29, 20264 days ago
RSI: OverboughtOct 19, 20262 weeks ago
SMA: BullishSep 28, 20261 month ago
SMA: BearishSep 25, 20261 month ago
MACD: Buy SignalSep 22, 20261 month ago
SMA: BullishSep 21, 20261 month ago
SMA: BullishSep 21, 20261 month ago
SMA: BearishSep 14, 20261 month ago
SMA: BearishSep 9, 20261 month ago
MACD: Sell SignalAug 25, 20262 months ago
RSI: OverboughtAug 6, 20262 months ago
MACD: Buy SignalAug 4, 20263 months ago
SMA: BullishAug 3, 20263 months ago
SMA: BullishAug 3, 20263 months ago

Analyst view

Consensus: none

Price target (mean) 17.00 +53.7% upside
Target (low)
12.00
Target (mean)
17.00
Target (high)
21.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy2
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 4
  • 1 month ago 4
  • 2 months ago 5

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ADMA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.196670.19 – 0.200.15902+23.7%138.12M+2.9%3
Next quarter0.243330.22 – 0.270.2157+12.8%158.40M+13.8%3
Current year0.796670.77 – 0.830.6567+21.3%535.35M+4.9%3
Next year0.943330.81 – 1.030.79667+18.4%629.54M+17.6%3

Upgrades and downgrades

The latest rating changes

ADMA analyst upgrades and downgrades
DateFirmActionFromTo
Jul 15, 2026MizuhoMaintainedOutperformOutperform
May 7, 2026Canaccord GenuityMaintainedBuyBuy
May 7, 2026MizuhoMaintainedOutperformOutperform
Apr 21, 2026Canaccord GenuityInitiated—Buy
Apr 13, 2026MizuhoMaintainedOutperformOutperform
Mar 26, 2026Cantor FitzgeraldDowngradeOverweightNeutral
May 8, 2025Raymond JamesMaintainedStrong BuyStrong Buy
Mar 4, 2025Cantor FitzgeraldReiteratedOverweightOverweight
Nov 8, 2024HC Wainwright & Co.MaintainedBuyBuy
Nov 8, 2024Raymond JamesMaintainedStrong BuyStrong Buy
Oct 14, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 20, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Aug 12, 2024HC Wainwright & Co.MaintainedBuyBuy
Aug 9, 2024Cantor FitzgeraldMaintainedOverweightOverweight
Jul 9, 2024Cantor FitzgeraldMaintainedOverweightOverweight
Jun 20, 2024MizuhoMaintainedBuyBuy
May 10, 2024Raymond JamesMaintainedStrong BuyStrong Buy
May 10, 2024Cantor FitzgeraldMaintainedOverweightOverweight
May 10, 2024HC Wainwright & Co.MaintainedBuyBuy
May 10, 2024MizuhoMaintainedBuyBuy
Mar 26, 2024HC Wainwright & Co.ReiteratedBuyBuy
Mar 1, 2024MizuhoMaintainedBuyBuy
Feb 29, 2024Cantor FitzgeraldMaintainedOverweightOverweight
Feb 29, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jan 22, 2024MizuhoMaintainedBuyBuy
Jan 9, 2024HC Wainwright & Co.MaintainedBuyBuy
Dec 19, 2023Cantor FitzgeraldReiteratedOverweightOverweight
Nov 17, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 10, 2023Cantor FitzgeraldMaintainedOverweightOverweight
Aug 10, 2023Raymond JamesMaintainedStrong BuyStrong Buy